A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

Summary

This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.

Timeline

Start

2026-06-03

Primary completion

2029-07-20

Completion

2031-07-18

Drugs

Indications